LegoChem strikes historic $1.7B license deal with Janssen
Korean biopharmaceutical firm LegoChem Biosciences signed a $1.7 licensing deal with Janssen Biotech for its solid cancer treatment candidate, LCB84, which targets colorectal and gastric cancer tumors.